D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
LYEL holding history
Lyell Immunopharma, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
LYEL overviewAll 13F holders of LYELFull Q2 2026 holdings
- Shares (Q2 2025)
- 0
- Sold out in Q2 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 11
- Since Q4 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2025 | 0 | $0 | 0.0% | −3,859−100.0% | Sold outConverted for a 1-for-20 split | Holders |
| Q1 2025 | 77,178 | $41.5K | <0.1% | −889,087−92.0% | Reduced | Holders |
| Q4 2024 | 966,265 | $618.4K | <0.1% | +493,639+104.4% | Added | Holders |
| Q3 2024 | 472,626 | $652.2K | <0.1% | +71,773+17.9% | Added | Holders |
| Q2 2024 | 400,853 | $581.2K | <0.1% | +27,247+7.3% | Added | Holders |
| Q1 2024 | 373,606 | $833.1K | <0.1% | +373,606 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −16,353−100.0% | Sold out | Holders |
| Q1 2023 | 16,353 | $38.6K | <0.1% | −43,512−72.7% | Reduced | Holders |
| Q4 2022 | 59,865 | $207.7K | <0.1% | −47,370−44.2% | Reduced | Holders |
| Q3 2022 | 107,235 | $786.0K | <0.1% | −161,607−60.1% | Reduced | Holders |
| Q2 2022 | 268,842 | $1.75M | <0.1% | −54,404−16.8% | Reduced | Holders |
| Q1 2022 | 323,246 | $1.63M | <0.1% | +161,176+99.4% | Added | Holders |
| Q4 2021 | 162,070 | $1.25M | <0.1% | +162,070 | New | Holders |